title: Use of GLV-1h68 for Vaccinia Virotherapy and Monitoring.
abstract: Herein we describe the use of the vaccinia virus strain GLV-1h68 as a theragnostic agent in cancer models. To date, GLV-1h68 has been used successfully in more than 50 xenograft tumor models. The recombinant vaccinia virus strain has been equipped with heterologous expression cassettes for a luciferase-fluorescent protein fusion gene, bacterial beta-galactosidase, as well as a bacterial glucuronidase. The methods to investigate and monitor GLV-1h68 mediated virotherapy, including optical imaging and biomarker analysis, will be presented in detail.
authors.affiliation: Genelux Corporation, 3030 Bunker Hill St, San Diego, CA, 92109, USA.
authors.forename: Alexa
authors.initials: A
authors.lastname: Frentzen
authors.forename: Ulrike
authors.initials: U
authors.lastname: Geissinger
authors.forename: Desislava
authors.initials: D
authors.lastname: Tsoneva
authors.forename: Jochen
authors.initials: J
authors.lastname: Stritzker
mesh_terms: D000818:Animals; D002460:Cell Line; D057075:Enzyme Assays; D005966:Glucuronidase / Q000378:metabolism; D006801:Humans; D008156:Luciferases / Q000378:metabolism; D008819:Mice, Nude; D050130:Oncolytic Virotherapy / Q000379:methods*; D061848:Optical Imaging; D014616:Vaccinia virus / Q000235:genetics / Q000502:physiology*; D023041:Xenograft Model Antitumor Assays
chemical_list: D008156:Luciferases; D005966:Glucuronidase